The VA Opens an MDMA Trial for Veterans With PTSD and Alcohol Use Disorder

The Department of Veterans' Affairs announced in May 2026 the launch of a trial of MDMA-assisted therapy for PTSD and alcohol use disorder in US veterans, enrolling approximately 80 veterans and comparing outcomes between those receiving MDMA-assisted therapy and those receiving identical psychotherapy with an active control. It is the most consequential MDMA study for a specific population, and the design is the reason.

Why the comorbidity is the point

PTSD and alcohol use disorder appear together so often in veteran populations that treating them separately is usually a fiction. Alcohol is used to manage hyperarousal, insomnia and intrusive memories; the drinking then worsens sleep and mood, which increases the drinking. Trials that exclude people with substance dependence — which MDMA's Phase 3 programme did — therefore study a version of PTSD that many veterans do not have.

A trial that deliberately enrols both conditions answers a question the Phase 3 programme could not: does this treatment help the people who actually need it, rather than the people who were easiest to study?

Why an active control matters more here

The central objection to the MDMA-for-PTSD evidence has always been that participants could tell whether they had received the drug, and that an inert placebo cannot blind a session where the effects are unmistakable. An active comparator — psychotherapy delivered identically, with something pharmacologically active in the control arm — is the design that gets closest to solving that. It is also the design the FDA's request for a new randomised, double-blind trial was pointing toward.

If this trial delivers a clean result against an active control, it will be the most persuasive MDMA evidence produced anywhere, and it will be produced by a public health system rather than a drug sponsor. That is not a trivial difference in how the finding will be received.

The Australian parallel

Veterans in Australia have a different and narrower route. The Department of Veterans' Affairs' own guidance on psychedelic-assisted psychotherapy states that psychedelic drugs are strictly controlled, that treatment may only be provided by a specialist psychiatrist who is an Authorised Prescriber, and that general practitioners and other medical specialists who are not Authorised Prescribers cannot legally deliver it. So for Australian veterans the question is access to a qualified prescriber; for US veterans the question is whether a trial is recruiting.

What a trial of this size can tell you

Eighty participants is a meaningful step up from a proof-of-principle study and well below a Phase 3. What it can establish: safety in a comorbid population, a defensible effect size against an active control, and whether the treatment is workable inside a health system. What it cannot establish: approval-level efficacy, durability over years, or performance across the range of veteran presentations.

Who should pay attention

• Veterans with both PTSD and a drinking problem, because this is the first serious attempt to treat them as one condition.
• Clinicians, because an active-comparator design in a real population is the evidence the field has been asked for.
• Anyone following the FDA application, because a well-conducted public-sector trial with an active control changes what the sponsor's resubmission is being compared against.

Registration and recruitment status for this and other MDMA studies can be checked on ClinicalTrials.gov, and we list the registries we use on our Resources page. If you are a veteran considering this, the correct first step is your VA care team, not a private clinic.